Oritavancin activity against vancomycin-susceptible and vancomycin-resistant enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 3, 2012, Pages 1639-1642

  Mendes, Rodrigo E ^a   Woosley, Leah N ^a   Farrell, David J ^a   Sader, Helio S ^a   Jonesa, Ronald N ^a,b  

^a JMI LABORATORIES   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORITAVANCIN; POLYPEPTIDE; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIAL GENE; DRUG POTENCY; ENTEROCOCCUS; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VANA GENE; VANB GENE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN SUSCEPTIBLE ENTEROCOCCUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84857186414     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06067-11     Document Type: Article

References (21)

1. Arhin FF, Moeck G, Draghi DC, Pillar CM, Sahm DF. 2010. Longitudinal analysis of the in vitro activity profile of oritavancin and comparator glycopeptides against Gram-positive organisms from Europe: 2005-2008. Int. J. Antimicrob. Agents 36:474-476.
2. Brandl K, et al. 2008. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature 455:804-807.
3. Clinical Laboratory Standards Institute. 2009. M07-A8. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard: eighth ed. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical Laboratory Standards Institute. 2011. M100-S21. Performance standards for antimicrobial susceptibility testing: 21st informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P. 2007. Modes and modulations of antibiotic resistance gene expression. Clin. Microbiol. Rev. 20:79-114. (Pubitemid 46167769)
6. Dutka-Malen S, Evers S, Courvalin P. 1995. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:1434.
7. European Committee on Antimicrobial Susceptibility Testing. 2011. Breakpoint tables for interpretation of MICs and zone diameters. Version 1.3, January 2011. http://www.eucast.org/clinical-breakpoints/. http: //www.eucast.org/clinical-breakpoints/.
8. Gu L, et al. 2009. A new Tn1546 type of VanB phenotype-vanA genotype vancomycin-resistant Enterococcus faecium isolates in mainland China. Diagn. Microbiol. Infect. Dis. 63:70-75.
9. Hegstad K, Mikalsen T, Coque TM, Werner G, Sundsfjord A. 2010. Mobile genetic elements and their contribution to the emergence of antimicrobial resistant Enterococcus faecalis and Enterococcus faecium. Clin. Microbiol. Infect. 16:541-554.
10. Hidron AI, et al. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
11. Laverde Gomez JA, et al. 2011. Intra- and interspecies genomic transfer of the Enterococcus faecalis pathogenicity island. PLoS One 6:e16720.
12. Lebreton F, et al. 2011. D-Ala-D-Ser VanN-type transferable vancomycin resistance in Enterococcus faecium. Antimicrob. Agents Chemother. 55: 4606-4612.
13. Mascini EM, Bonten MJ. 2005. Vancomycin-resistant enterococci: consequences for therapy and infection control. Clin. Microbiol. Infect. 11(Suppl. 4):43-56. (Pubitemid 40946171)
14. McBride SJ, Upton A, Roberts SA. 2010. Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia - a five-year retrospective review. Eur. J. Clin. Microbiol. Infect. Dis. 29:107-114.
15. McKay GA, et al. 2009. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. J. Antimicrob. Chemother. 63:1191-1199.
16. Ruiz-Garbajosa P, et al. 2006. Genetic and phenotypic differences among Enterococcus faecalis clones from intestinal colonisation and invasive disease. Clin. Microbiol. Infect. 12:1193-1198. (Pubitemid 44762521)
17. Sava IG, Heikens E, Huebner J. 2010. Pathogenesis and immunity in enterococcal infections. Clin. Microbiol. Infect. 16:533-540.
18. Ubeda C, et al. 2010. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J. Clin. Invest. 120:4332-4341.
19. Werner G, et al. 2008. Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill. 13:19046.
20. Wisplinghoff H, et al. 2004. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 39:309-317. (Pubitemid 39050477)
21. Woodford N. 2001. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb. Drug Resist. 7:229-236. (Pubitemid 33104597)